Encorafenib plus binimetinib for BRAF V600-mutated thyroid cancer in Japan: final analysis.

Int J Clin OncolJul 31, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Iwao Sugitani, Naomi Kiyota, Hiroo Imai et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter, open-label phase 2 trial assessed the efficacy and safety of encorafenib plus binimetinib (ENC + BIN) in 22 patients with unresectable BRAF V600-mutated thyroid cancer. The objective response rate (ORR) increased to 68.2% after a median follow-up of 28.7 months, indicating sustained tumor responses.

Key findings

  • The objective response rate (ORR) for ENC + BIN was 68.2% in patients with BRAF V600-mutated thyroid cancer.
  • Median progression-free survival (PFS) was not reached for differentiated thyroid carcinoma (DTC).
  • Median overall survival (OS) was 17.7 months for anaplastic thyroid carcinoma (ATC).
  • Common adverse events included eye disorders (5/12) and infections (4/12) after > 360 days.

Why it matters

The findings suggest that ENC + BIN may offer a viable treatment option for patients with BRAF V600-mutated thyroid cancer, particularly those who are refractory to other therapies, highlighting the need for ongoing management strategies in this population.

Source

PubMed · PMID 42536275Free full text on PubMed Central

Published in Int J Clin Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.